drugset / Trial / NCT04421404
Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients
Phase 2
Completed
34 enrolled
Priscilla Hsue, MD
San Francisco General Hospital · collabVitalant Research Institute · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms up to 14 days after the onset of initial symptoms.
Timeline
- Start
- 2020-06-09
- Primary completion
- 2021-04-30
- Completion
- 2021-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Convalescent Plasma | Protein / enzyme biologic | 250 ml | Other |